Products / Oncology and Hematology
Hematology
Hematologic diseases encompass a broad spectrum ranging from acute and chronic malignancies of lymphoid and myeloid origin to clonal disorders and minimal residual disease (MRD) monitoring. Diagnostic, prognostic, and therapeutic analytical approaches are tailored to these subgroups.
In lymphoid diseases, B- and T-cell-derived leukemias and lymphomas are examined, while in myeloid neoplasms, mutations and fusions are targeted. MRD analysis accurately detects residual disease after treatment. Clonality is important for understanding the origin and diversity of malignant cells.
Genetic testing enables personalized and targeted approaches for each of these subcategories.
Lymphoid Diseases
In lymphocyte-derived hematological diseases (e.g., ALL, CLL, lymphomas), the identification of genetic variants plays a critical role in diagnosis, prognostic classification, and treatment decisions.
Lymphoid panels comprehensively support the clinical process by evaluating parameters such as SNV, Indel, fusion genes, and clonality.
Myeloid Diseases
In myeloid malignancies (e.g., AML, MDS, MPN), the detection of molecular markers is of great importance for diagnosis, risk classification, and targeted therapies.
Myeloid panels enhance clinical decision support processes by evaluating critical variants such as SNV, Indel, CNV, and ITD.
Clonality Analysis
In lymphoid malignancies (particularly CLL, ALL, and lymphomas), the detection of clonal B or T cell populations is important for diagnosis and follow-up.
Clonality analyses provide a powerful tool for detecting rearrangements in immune receptor gene regions, thereby identifying the presence and progression of the disease and monitoring minimal residual disease (MRD).
MRD Monitoring
Minimal residual disease (MRD) monitoring is of critical importance in assessing treatment response and predicting relapse risk in hematologic malignancies.
Next-generation sequencing (NGS)-based MRD panels enable the detection of residual disease with high sensitivity, making it possible to develop personalized monitoring strategies.
Expert Insights into NGS: Hematology
Prof. Dr. Ajlan Tükün emphasizes the transformative impact of Next Generation Sequencing (NGS) in hematology.